Liraglutide (Victoza / Saxenda)

1. Overview

Liraglutide is a long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA) developed by Novo Nordisk as a once-daily subcutaneous injection for the treatment of type 2 diabetes mellitus and chronic weight management [1-6][7][9]. It is a 31-amino acid acylated analog of human GLP-1(7-37) with 97% sequence homology to the native incretin hormone. Two key molecular modifications confer its extended pharmacokinetic profile: (1) a substitution of arginine for lysine at position 34 (Arg34Lys), and (2) attachment of a C-16 palmitic acid (palmitoyl) fatty acid chain to lysine at position 26 via a glutamic acid spacer. These modifications enable non-covalent binding to serum albumin, resulting in resistance to dipeptidyl peptidase-4 (DPP-4) degradation and a half-life of approximately 13 hours -- compared to 1.5-2 minutes for native GLP-1 [22].

The molecular formula is C172H265N43O51 with a molecular weight of 3751.2 Da. Following subcutaneous injection, liraglutide has an absolute bioavailability of approximately 55%, reaches peak plasma concentration (Tmax) at 8-12 hours, is greater than 98% bound to plasma proteins, and has an apparent volume of distribution of approximately 13 liters (0.07 L/kg intravenous) with clearance of approximately 1.2 L/h.

Liraglutide is marketed under two brand names at different doses: Victoza (0.6 mg, 1.2 mg, or 1.8 mg daily) for glycemic control in type 2 diabetes, FDA-approved January 25, 2010; and Saxenda (3.0 mg daily) for chronic weight management, FDA-approved December 23, 2014. In August 2017, the FDA added a cardiovascular indication to Victoza based on the LEADER trial, making it the first GLP-1 RA approved to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease [7]. In December 2020, Saxenda's indication was expanded to include adolescents aged 12 years and older with obesity [14].

Molecular Weight

3751.2 Da

Molecular Formula

C172H265N43O51

Sequence

31 amino acids (GLP-1 analog, 97% homologous to native GLP-1(7-37))

Key Modification

C-16 palmitic acid at Lys26 via glutamic acid spacer; Arg34Lys substitution

Half-life

~13 hours (subcutaneous)

Bioavailability

~55% (absolute, subcutaneous)

Protein Binding

>98%

Tmax

8-12 hours

Routes

Subcutaneous injection (approved)

FDA Status (Victoza)

Approved January 25, 2010 (type 2 diabetes); CV indication added August 2017

FDA Status (Saxenda)

Approved December 23, 2014 (chronic weight management); adolescents added December 2020

2. Mechanism of Action

Liraglutide is an agonist of the GLP-1 receptor (GLP-1R), a class B G protein-coupled receptor expressed on pancreatic beta cells, alpha cells, the gastrointestinal tract, central nervous system (hypothalamus, brainstem), heart, kidney, and vasculature [22].

Pancreatic effects. Binding of liraglutide to GLP-1R on pancreatic beta cells activates adenylyl cyclase via Gs-alpha, increasing intracellular cyclic adenosine monophosphate (cAMP) and activating protein kinase A (PKA). This glucose-dependently enhances insulin biosynthesis and secretion -- liraglutide potentiates insulin release only when blood glucose is elevated above the fasting threshold, which substantially reduces the risk of hypoglycemia compared to sulfonylureas and exogenous insulin. Simultaneously, liraglutide suppresses glucagon secretion from pancreatic alpha cells in a glucose-dependent manner, reducing hepatic glucose output. In preclinical models, liraglutide has demonstrated promotion of beta-cell proliferation, inhibition of beta-cell apoptosis, and increased beta-cell mass, though the clinical relevance of these effects in humans remains under investigation.

Gastrointestinal effects. Liraglutide slows gastric emptying, which attenuates postprandial glucose excursions and contributes to satiety. This effect is mediated both by vagal afferent signaling and direct action on GLP-1 receptors in the gastrointestinal tract. The delayed gastric emptying is a significant contributor to the gastrointestinal side effects (nausea, vomiting) that are most prominent during dose titration and typically attenuate over 4-8 weeks due to tachyphylaxis.

Central nervous system effects. GLP-1 receptors in the hypothalamic arcuate nucleus and the area postrema mediate the appetite-suppressing and satiety-enhancing effects of liraglutide. Liraglutide crosses the blood-brain barrier and activates anorexigenic POMC/CART neurons while inhibiting orexigenic NPY/AgRP neurons, reducing food intake, portion size, and food cravings. These central mechanisms are the primary driver of the weight loss observed with the 3.0 mg dose used for obesity treatment [9].

Cardiovascular effects. The mechanisms underlying liraglutide's cardiovascular benefits observed in LEADER are multifactorial and not fully elucidated. Mediation analysis of LEADER data suggests that approximately 35-40% of the cardiovascular benefit can be attributed to reductions in traditional risk factors (HbA1c, body weight, LDL cholesterol, UACR) [25]. Additional proposed mechanisms include direct anti-inflammatory effects (reduction of CRP, IL-6, and TNF-alpha), improvement of endothelial function, reduction of arterial stiffness, attenuation of atherosclerotic plaque formation, and modest reductions in systolic blood pressure (2-6 mmHg across trials).

Albumin binding and DPP-4 resistance. The C-16 palmitic acid chain enables reversible non-covalent binding to serum albumin in the subcutaneous depot and in circulation, which serves a dual purpose: it slows absorption from the injection site (contributing to the 8-12 hour Tmax) and shields the molecule from enzymatic degradation by DPP-4 and neutral endopeptidases. This albumin-binding mechanism is what extends the half-life from ~2 minutes (native GLP-1) to ~13 hours, enabling once-daily dosing.

3. Pharmacokinetics

The pharmacokinetic profile of liraglutide is principally determined by its C-16 palmitic acid (palmitoyl) side chain, which enables reversible, non-covalent binding to serum albumin and thereby governs absorption, distribution, metabolism, and elimination [22].

Absorption

Following subcutaneous injection into the abdomen, thigh, or upper arm, liraglutide is absorbed slowly from the injection depot due to self-association into heptamers and albumin binding at the injection site. Absolute bioavailability is approximately 55%, which is lower than some other acylated GLP-1 RAs (e.g., semaglutide ~89%) owing to local degradation at the injection site [22][29]. Peak plasma concentration (Tmax) is reached at 8-12 hours post-dose, reflecting the slow depot absorption. Bioavailability is comparable across the three approved injection sites (abdomen, thigh, upper arm), and absorption is not meaningfully affected by the time of day of injection or proximity to meals.

Distribution

Liraglutide has an apparent volume of distribution (Vd) of approximately 11-17 L following subcutaneous administration (approximately 13 L central estimate, or 0.07 L/kg after intravenous dosing), indicating that the molecule is largely confined to the plasma and interstitial fluid compartments [22]. Plasma protein binding exceeds 98%, with serum albumin as the primary binding partner. The binding is mediated by the C-16 palmitic acid chain, which inserts into hydrophobic binding sites on albumin -- the same fatty acid binding sites used by endogenous free fatty acids. This extensive albumin binding limits tissue distribution and also serves as a circulating reservoir, releasing free liraglutide gradually as the unbound fraction is cleared.

Metabolism and Elimination

Liraglutide is metabolized endogenously through proteolytic degradation by dipeptidyl peptidase-4 (DPP-4) and neutral endopeptidases (NEP), analogous to the catabolism of other endogenous peptides [22]. Importantly, liraglutide is not a substrate for cytochrome P450 (CYP) enzymes, and CYP-mediated metabolism does not contribute to its clearance. This characteristic substantially reduces the potential for pharmacokinetic drug-drug interactions with CYP substrates, inhibitors, or inducers. No single organ has been identified as the primary route of elimination; metabolites are excreted via both urine and feces, with no intact liraglutide detected in either.

The terminal elimination half-life is approximately 13 hours, enabling once-daily dosing [22]. Clearance is approximately 1.2 L/h. Steady-state plasma concentrations are achieved after approximately 3-5 days of once-daily dosing, with an accumulation ratio of approximately 1.5-fold relative to a single dose. The relatively short half-life (compared to ~7 days for semaglutide) is a direct consequence of the C-16 monofatty acid chain, which provides less albumin affinity than semaglutide's C-18 difatty acid chain.

Pharmacokinetics in Special Populations

Renal impairment. Population pharmacokinetic analyses indicate that mild, moderate, or severe renal impairment does not meaningfully alter liraglutide exposure [22]. No dose adjustment is required. However, clinical experience in patients with severe renal impairment (eGFR less than 15 mL/min/1.73 m2) or end-stage renal disease requiring dialysis is limited, and caution is recommended. Dehydration from gastrointestinal side effects can precipitate acute kidney injury in patients with pre-existing renal compromise.

Hepatic impairment. Dedicated pharmacokinetic studies in patients with mild (Child-Pugh A), moderate (Child-Pugh B), and severe (Child-Pugh C) hepatic impairment showed reduced liraglutide exposure (AUC reduced by 13-44% depending on severity), but no dose adjustment is recommended because liraglutide is titrated to clinical effect.

Obesity. Body weight modestly affects liraglutide pharmacokinetics, with higher body weight associated with lower weight-normalized exposure, but this does not necessitate weight-based dosing given the fixed-dose titration approach and the broad therapeutic window demonstrated across the LEAD, SCALE, and LEADER programs.

Pediatric populations. Pharmacokinetic data from adolescents (12-17 years) demonstrated liraglutide exposure comparable to adults, supporting use of the same dosing regimen [29]. The SCALE Kids trial (ages 6 to under 12) confirmed adequate exposure at 3.0 mg in younger children [15].

Age, sex, and race. Population pharmacokinetic analyses across clinical programs indicate that age (18-80+ years), sex, and race/ethnicity do not significantly affect liraglutide pharmacokinetics [22].

Drug Interactions

Because liraglutide is not metabolized by CYP enzymes and is greater than 98% protein-bound, the risk of traditional pharmacokinetic drug-drug interactions is low. Liraglutide delays gastric emptying, which may affect the rate (but generally not the extent) of absorption of concomitant oral medications. In dedicated studies, liraglutide did not alter the pharmacokinetics of atorvastatin, griseofulvin, digoxin, lisinopril, or oral contraceptives to a clinically relevant degree. Acetaminophen AUC was unchanged, though Cmax was reduced by 31% and Tmax delayed by 15 minutes. No dose adjustment of concomitant medications is required, though medications with a narrow therapeutic index that are sensitive to delayed gastric emptying should be monitored clinically.

4. Dose-Response Relationships

Glycemic Control: LEAD Dose-Response

The LEAD program systematically evaluated three doses of liraglutide (0.6 mg, 1.2 mg, and 1.8 mg daily) for glycemic control, establishing a clear dose-response relationship [1-6]:

• 0.6 mg daily (titration dose): HbA1c reductions of approximately 0.5-0.7% across trials. This dose is considered subtherapeutic for glycemic control and is used only during the 1-week initiation phase for gastrointestinal tolerability. In LEAD-1, the 0.6 mg dose still produced a statistically significant HbA1c reduction of -0.6% vs +0.2% placebo [1].
• 1.2 mg daily: HbA1c reductions of approximately 0.8-1.1% across trials, representing the minimum effective therapeutic dose [1-5].
• 1.8 mg daily: HbA1c reductions of approximately 1.0-1.5% across trials, providing modest incremental glycemic benefit over 1.2 mg (approximately 0.1-0.3% additional HbA1c lowering) [1-6].

The incremental glycemic benefit of 1.8 mg over 1.2 mg is relatively modest across the LEAD program, which is reflected in the FDA label recommending 1.2 mg as the standard therapeutic dose with 1.8 mg as an option for patients requiring additional glycemic control.

Weight Loss: Dose-Response Across Indications

Weight loss with liraglutide demonstrates a more pronounced dose-response relationship than glycemic control:

• Victoza 1.2 mg (diabetes): Weight loss of approximately 1.8-2.8 kg over 26 weeks in the LEAD trials [1-5].
• Victoza 1.8 mg (diabetes): Weight loss of approximately 2.0-3.2 kg over 26 weeks [1-6]. In LEADER, mean weight difference vs placebo was -2.3 kg over median 3.8 years [7].
• Saxenda 3.0 mg (obesity): Weight loss of approximately 5.6-8.4 kg (5.4-8.0%) over 56 weeks in the SCALE program [9][11]. The 3.0 mg dose produces roughly 2-3 times the weight loss seen with the 1.8 mg diabetes dose, reflecting both the higher dose and the different patient populations (higher baseline BMI, absence of T2D in some trials).

In SCALE Diabetes (patients with both T2D and obesity), liraglutide 3.0 mg produced 6.0% weight loss vs 4.7% with 1.8 mg vs 2.0% with placebo, demonstrating a dose-response even within the same population [11].

Cardiovascular Dose Considerations

In the LEADER trial, liraglutide 1.8 mg daily (or maximum tolerated dose) was the sole dose evaluated [7]. The cardiovascular benefit (13% MACE reduction) was therefore demonstrated only at this dose. It is unknown whether lower doses (1.2 mg) or the higher obesity dose (3.0 mg) would provide comparable cardiovascular protection, as no cardiovascular outcomes trial has been conducted at these doses. The FDA cardiovascular indication is specific to Victoza 1.8 mg.

Dose-Escalation Rationale for GI Tolerability

The dose-escalation protocols for both Victoza and Saxenda are designed specifically to mitigate gastrointestinal adverse events through allowing tachyphylaxis to the emetic GLP-1 receptor-mediated effects:

• Victoza: 0.6 mg for 1 week, then increase to 1.2 mg, with optional increase to 1.8 mg. Rapid initiation at 1.2 mg or 1.8 mg without titration approximately doubles the incidence and severity of nausea.
• Saxenda: 0.6 mg weekly escalation over 5 weeks (0.6 to 1.2 to 1.8 to 2.4 to 3.0 mg). This gradual titration reduces discontinuation due to gastrointestinal adverse events from approximately 15-20% (without titration) to approximately 6-10% (with titration) [9].

5. Comparative Effectiveness

Liraglutide vs Semaglutide (STEP-8: Definitive Head-to-Head)

The STEP-8 trial (n=338, 68 weeks) provides the definitive head-to-head comparison between semaglutide 2.4 mg weekly and liraglutide 3.0 mg daily for weight management in adults with overweight or obesity without diabetes [31]. Results were unequivocal in favor of semaglutide:

• Mean weight loss: semaglutide 15.8% vs liraglutide 6.4% (estimated treatment difference -9.4 percentage points; 95% CI -12.0 to -6.8; p=0.001)
• Proportion achieving 10% or greater weight loss: semaglutide 70.9% vs liraglutide 25.6%
• Proportion achieving 20% or greater weight loss: semaglutide 38.5% vs liraglutide 6.0%
• Gastrointestinal adverse events were comparable (semaglutide 84.1% vs liraglutide 82.7%)

For diabetes management, SUSTAIN-10 compared semaglutide 1.0 mg weekly with liraglutide 1.2 mg daily (the lower diabetes dose). Semaglutide demonstrated superiority in HbA1c reduction (-1.7% vs -1.0%) and body weight reduction (-5.8 kg vs -1.9 kg) over 30 weeks [32].

These results, combined with the once-weekly convenience of semaglutide, have largely led to semaglutide replacing liraglutide as the preferred GLP-1 RA for both diabetes and weight management in clinical practice. Liraglutide retains a role in patients who cannot tolerate semaglutide, in pediatric populations where semaglutide data is more limited, and where cost or insurance access favors liraglutide.

Liraglutide vs Exenatide (LEAD-6)

LEAD-6 (n=464, 26 weeks) was the first head-to-head trial of two GLP-1 RAs, comparing once-daily liraglutide 1.8 mg with twice-daily exenatide 10 mcg in patients with T2D inadequately controlled on metformin, sulfonylurea, or both [6]:

• HbA1c reduction: liraglutide -1.12% vs exenatide -0.79% (difference -0.33%; p=0.0001)
• Proportion achieving HbA1c less than 7%: liraglutide 54% vs exenatide 43% (p=0.0015)
• Weight loss: comparable between groups (liraglutide -3.24 kg vs exenatide -2.87 kg; p=0.22)
• Nausea: initially comparable in frequency (~25% both groups), but more persistent with exenatide; by weeks 6-26, nausea was less common with liraglutide
• Minor hypoglycemia: lower with liraglutide (1.93 vs 2.60 events/patient-year; p=0.01)

Liraglutide demonstrated superior glycemic efficacy, comparable weight loss, better gastrointestinal tolerability after initial weeks, and lower hypoglycemia compared to twice-daily exenatide [6].

Liraglutide vs Dulaglutide (AWARD-6)

AWARD-6 (n=599, 26 weeks, open-label) compared once-weekly dulaglutide 1.5 mg with once-daily liraglutide 1.8 mg in patients with T2D on metformin [18]:

• HbA1c reduction: dulaglutide -1.42% vs liraglutide -1.36% (difference -0.06%; 95% CI -0.19 to 0.07), meeting the prespecified non-inferiority criterion
• Weight loss: dulaglutide -2.90 kg vs liraglutide -3.61 kg (difference 0.71 kg; p=0.011 favoring liraglutide)
• GI adverse events: comparable between groups (nausea 20% vs 18%)

The primary conclusion was that once-weekly dulaglutide was non-inferior to once-daily liraglutide for glycemic control, with a slightly smaller weight loss effect. The once-weekly dosing convenience of dulaglutide was considered a practical advantage [18].

Liraglutide vs Tirzepatide (Cross-Trial Comparison)

No direct head-to-head trial has compared liraglutide with tirzepatide. Cross-trial comparisons suggest substantially greater efficacy for tirzepatide across both glycemic and weight endpoints:

• Weight loss (obesity, cross-trial): Liraglutide 3.0 mg produced 8.0% (SCALE Obesity) vs tirzepatide 15 mg which produced 20.9% (SURMOUNT-1) over similar timeframes -- an approximately 2.5-fold difference
• HbA1c (diabetes, cross-trial): Liraglutide 1.8 mg typically produces 1.0-1.5% HbA1c reductions vs tirzepatide 15 mg which produces approximately 2.3% (SURPASS-2)

These cross-trial comparisons must be interpreted cautiously due to differences in study populations, baseline characteristics, and trial design. Tirzepatide's dual GIP/GLP-1 receptor agonism likely accounts for its superior efficacy.

Liraglutide vs Oral Semaglutide (PIONEER 4)

PIONEER 4 (n=711, 52 weeks) compared oral semaglutide 14 mg daily with subcutaneous liraglutide 1.8 mg daily and placebo in patients with T2D [19]:

• HbA1c reduction: oral semaglutide -1.2% vs liraglutide -1.1% (non-inferior)
• Weight loss: oral semaglutide -4.4 kg vs liraglutide -3.1 kg vs placebo -0.5 kg at 26 weeks (oral semaglutide superior to liraglutide; p=0.003)
• GI events: oral semaglutide 43% vs liraglutide 36% vs placebo 31%

This trial demonstrated that even oral semaglutide, with its low bioavailability (~1%), achieved comparable glycemic control and superior weight loss to injectable liraglutide [19].

Why Semaglutide Has Largely Replaced Liraglutide

Several factors have contributed to the shift from liraglutide to semaglutide as the dominant GLP-1 RA in clinical practice: (1) dramatically superior weight loss efficacy (15.8% vs 6.4% in head-to-head STEP-8); (2) once-weekly vs once-daily injection burden; (3) availability of an oral formulation (Rybelsus); (4) SELECT cardiovascular outcomes data extending the evidence base to patients with obesity without diabetes. Liraglutide remains clinically relevant for specific populations including pediatric patients (Saxenda approved for ages 12+, with data in children 6-11), patients intolerant to semaglutide, and situations where cost, insurance formulary, or generic availability (liraglutide patents expire earlier) influence prescribing decisions.

6. Researched Applications

Type 2 Diabetes Mellitus (Strong Evidence -- FDA Approved)

The LEAD (Liraglutide Effect and Action in Diabetes) clinical trial program comprised six Phase 3 randomized controlled trials (LEAD-1 through LEAD-6) enrolling over 4,000 patients, systematically evaluating liraglutide as monotherapy and in combination with every major class of oral antidiabetic agent [1-6].

LEAD-1 (n=1,041) demonstrated that liraglutide 1.2 mg or 1.8 mg added to glimepiride reduced HbA1c by 1.1% from baseline 8.5%, significantly superior to both rosiglitazone (-0.4%) and placebo (+0.2%), with weight neutrality (-0.2 kg at 1.8 mg) compared to +2.1 kg weight gain with rosiglitazone [1]. LEAD-2 (n=1,091) showed that liraglutide added to metformin reduced HbA1c by 1.0%, equivalent to glimepiride, but with weight loss of 1.8-2.8 kg versus +1.0 kg gain with glimepiride, and dramatically lower hypoglycemia (3% vs 17%) [2]. LEAD-3 (n=746) established superiority of liraglutide 1.8 mg monotherapy over glimepiride 8 mg over 52 weeks (HbA1c reduction -1.14% vs -0.51%; p<0.0001), with benefits sustained over 2 years in the extension study [3][30]. LEAD-4 (n=533) demonstrated robust HbA1c reductions of 1.5% when added to metformin plus rosiglitazone [4]. LEAD-5 (n=581) showed superiority of liraglutide 1.8 mg over insulin glargine for HbA1c reduction (1.33% vs 1.09%; p=0.0015) with a 3.43 kg weight advantage [5]. LEAD-6 (n=464) demonstrated superiority over exenatide twice-daily for HbA1c reduction (1.12% vs 0.79%; p<0.0001) with less persistent nausea [6].

Across the LEAD program, liraglutide consistently achieved HbA1c reductions of 0.8-1.5% with weight loss or weight neutrality, low rates of hypoglycemia, and systolic blood pressure reductions of 2-6 mmHg.

Cardiovascular Risk Reduction (Strong Evidence -- FDA Approved)

The LEADER trial (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) is the landmark cardiovascular outcomes trial for liraglutide [7]. This double-blind, placebo-controlled trial randomized 9,340 patients with type 2 diabetes and high cardiovascular risk (81% with established CVD) to liraglutide 1.8 mg daily or placebo, added to standard care, with a median follow-up of 3.8 years.

The primary composite endpoint of first occurrence of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke (3-point MACE) occurred in 13.0% of the liraglutide group versus 14.9% of the placebo group (HR 0.87; 95% CI 0.78-0.97; p=0.01 for superiority) [7]. Cardiovascular death was reduced by 22% (4.7% vs 6.0%; HR 0.78; 95% CI 0.66-0.93; p=0.007), and all-cause mortality was reduced by 15% (8.2% vs 9.6%; HR 0.85; 95% CI 0.74-0.97; p=0.02). Rates of nonfatal MI, nonfatal stroke, and hospitalization for heart failure were numerically lower but did not individually reach statistical significance. These results led to the August 2017 FDA approval of a cardiovascular indication for Victoza.

Subgroup analyses from LEADER demonstrated consistent benefit across patients with prior MI or stroke (HR 0.83) [24], across baseline blood pressure categories, with and without baseline metformin use, and across various durations of diabetes. However, the FIGHT trial (n=300) showed that liraglutide did NOT improve outcomes in patients with advanced heart failure and reduced ejection fraction (LVEF ~25%), with numerically higher rehospitalization rates, indicating this population should not receive liraglutide for heart failure management [17].

Renal Protection (Strong Evidence)

A prespecified secondary analysis of LEADER demonstrated that liraglutide reduced the composite renal endpoint (new-onset persistent macroalbuminuria, persistent doubling of serum creatinine, end-stage renal disease, or death due to renal disease) by 22% compared to placebo (5.7% vs 7.2%; HR 0.78; 95% CI 0.67-0.92; p=0.003) [8]. The benefit was primarily driven by a 26% reduction in new-onset persistent macroalbuminuria (HR 0.74; p=0.004). Renal safety was comparable between groups, with similar rates of acute kidney injury [8].

Chronic Weight Management (Strong Evidence -- FDA Approved)

The SCALE (Satiety and Clinical Adiposity -- Liraglutide Evidence) program evaluated liraglutide 3.0 mg for weight management across multiple populations.

SCALE Obesity and Prediabetes (n=3,731) demonstrated that liraglutide 3.0 mg produced mean weight loss of 8.4 kg versus 2.8 kg with placebo at 56 weeks (difference -5.6 kg; p<0.001) [9]. More than 63% of liraglutide-treated patients achieved at least 5% body weight loss versus 27.1% with placebo, and 33.1% achieved more than 10% loss versus 10.6% with placebo. The 3-year extension (n=2,254) showed sustained weight loss of 6.1% versus 1.9% and a 2.7-fold delay in onset of type 2 diabetes (HR 0.21), with only 2% progressing to T2D versus 6% on placebo [10].

SCALE Diabetes (n=846) showed that liraglutide 3.0 mg produced 6.0% weight loss in patients with type 2 diabetes versus 2.0% with placebo, with 54.3% achieving at least 5% loss [11]. SCALE Maintenance (n=422) demonstrated that after initial diet-induced weight loss of 6.0%, liraglutide 3.0 mg produced an additional 6.2% weight loss versus only 0.2% with placebo, with 81.4% maintaining initial weight loss versus 48.9% [12]. SCALE Sleep Apnea (n=359) showed significant reductions in AHI (-12.2 vs -6.1 events/h; p=0.015) and body weight (-5.7% vs -1.6%) in patients with obesity and moderate-to-severe obstructive sleep apnea [13].

Pediatric Obesity (Strong Evidence -- Approved for Adolescents)

The SCALE Teens trial (n=251) randomized adolescents aged 12 to under 18 with obesity to liraglutide 3.0 mg or placebo for 56 weeks [14]. Liraglutide was superior for BMI-SDS reduction (difference -0.22; p=0.002), with 43.3% achieving at least 5% BMI reduction versus 18.7% placebo, and 26.1% achieving at least 10% versus 8.1%. Gastrointestinal adverse events were common (64.8% vs 36.5%). Notably, BMI-SDS increased after treatment discontinuation, highlighting the need for sustained therapy.

The SCALE Kids trial (n=82) in children aged 6 to under 12 years (2025) demonstrated that liraglutide 3.0 mg reduced BMI by 5.8% versus a 1.6% increase with placebo (difference -7.4 percentage points; p<0.001), with 46% achieving at least 5% BMI reduction versus 9% [15]. Pharmacokinetic studies confirmed similar exposure profiles in adolescents and adults [29].

Non-Alcoholic Steatohepatitis / NASH (Moderate Evidence)

The LEAN trial (n=52) was the first randomized controlled trial of liraglutide in biopsy-confirmed NASH [16]. Liraglutide 1.8 mg daily for 48 weeks achieved histological resolution of NASH in 39% of patients (9/23) versus only 9% (2/22) on placebo (RR 4.3; 95% CI 1.0-17.7; p=0.019). Fibrosis progression occurred in only 9% with liraglutide versus 36% with placebo (RR 0.2; p=0.04) [16]. Additional studies have confirmed reductions in intrahepatic fat content with liraglutide in patients with T2D and NAFLD [27].

Polycystic Ovary Syndrome (Moderate Evidence)

Multiple RCTs have evaluated liraglutide in women with PCOS and obesity [21]. Elkind-Hirsch et al. (2022) demonstrated that liraglutide 3.0 mg significantly improved weight, body composition, and hormonal/metabolic parameters in women with obesity and PCOS [21]. Liraglutide reduced ectopic fat (hepatic and visceral) in PCOS patients [28681988], and a pilot RCT showed increased IVF pregnancy rates in obese PCOS women pretreated with liraglutide who had failed first-line reproductive treatments [29703793]. Combination therapy with metformin showed additive benefits for both metabolic and reproductive outcomes.

Alzheimer's Disease (Emerging Evidence)

The ELAD trial (n=204), a phase 2b RCT published in Nature Medicine (2026), evaluated daily liraglutide for 52 weeks in non-diabetic patients with mild-to-moderate Alzheimer's disease [20]. While the primary endpoint of cerebral glucose metabolism did not reach significance (p=0.14), liraglutide significantly improved executive function (ADAS-Exec, p=0.01) and was well-tolerated. Pooled analysis of GLP-1 RA trials showed lower incidence of dementia events [23]. This represents an active area of investigation with potential for disease-modifying effects mediated through insulin signaling restoration, anti-inflammatory pathways, and neuroprotection.

7. Clinical Evidence Summary

8. Dosing in Research

Type 2 Diabetes (Victoza). The FDA-approved dose begins at 0.6 mg subcutaneously once daily for at least 1 week (titration dose -- not effective for glycemic control), increasing to 1.2 mg daily, with optional further increase to 1.8 mg daily for additional glycemic benefit. The injection can be administered in the abdomen, thigh, or upper arm at any time of day, without regard to meals. No maximum treatment duration exists.

Chronic Weight Management (Saxenda). The dose is titrated over 5 weeks: 0.6 mg daily for week 1, 1.2 mg for week 2, 1.8 mg for week 3, 2.4 mg for week 4, and the maintenance dose of 3.0 mg daily from week 5 onward. If the 3.0 mg dose is not tolerated, treatment should be discontinued. The FDA label recommends discontinuation if less than 4% body weight loss is achieved after 16 weeks at the full 3.0 mg dose, as sustained clinically meaningful weight loss is unlikely in non-responders.

LEADER trial dosing. Liraglutide 1.8 mg daily (or maximum tolerated dose) was used, administered on top of standard-of-care diabetes treatment, for a minimum of 3.5 years and maximum of 5 years [7].

LEAN trial (NASH). Liraglutide 1.8 mg daily was used for 48 weeks [16].

Pediatric dosing. In adolescents (SCALE Teens), liraglutide 3.0 mg or maximum tolerated dose was used with the same titration schedule as adults [14]. In children 6-11 years (SCALE Kids), the same target dose of 3.0 mg was used [15].

9. Safety and Side Effects

The safety profile of liraglutide has been extensively characterized across the LEAD, SCALE, and LEADER programs involving tens of thousands of patients.

Gastrointestinal adverse events are the most common class of side effects and the leading cause of treatment discontinuation. Nausea rates demonstrate a clear dose-response across pooled trial data:

• 0.6 mg (titration): nausea in approximately 5-10% of patients
• 1.2 mg (Victoza standard): nausea in approximately 11-16%
• 1.8 mg (Victoza maximum / LEADER): nausea in approximately 14-20% (vs 3-4% placebo)
• 3.0 mg (Saxenda): nausea in approximately 39-40% (vs 14-17% placebo in SCALE trials)

In the LEAD trials at 1.2-1.8 mg, diarrhea occurred in 10-12%, vomiting in 6-9%, decreased appetite in 9-10%, dyspepsia in 4-7%, and constipation in approximately 5%. In the SCALE program at 3.0 mg, nausea was the most common adverse event (39.3% vs 13.8% placebo in SCALE Obesity), followed by diarrhea (20.9% vs 9.9%), constipation (19.4% vs 8.4%), and vomiting (15.7% vs 3.7%) [9]. These events are typically mild-to-moderate in intensity, most frequent during the first 4-8 weeks of treatment, and generally transient with continued use. The dose titration schedule was specifically designed to mitigate gastrointestinal tolerability issues. Discontinuation due to GI events was approximately 6.4% with liraglutide 3.0 mg vs 0.7% placebo in SCALE Obesity [9].

Hypoglycemia. The glucose-dependent mechanism of action results in low intrinsic hypoglycemia risk. In the LEAD trials, minor hypoglycemia rates with liraglutide monotherapy or combined with metformin were approximately 3%, comparable to placebo. Risk increases when liraglutide is combined with sulfonylureas (up to 10%) or insulin. In LEADER, no excess severe hypoglycemia was observed.

Pancreatitis. A persistent safety concern, though data from LEADER have been reassuring. In the LEADER trial (n=9,340, median 3.8-year follow-up), adjudicated acute pancreatitis occurred in 18 liraglutide patients (0.4%) versus 23 placebo patients (0.5%), yielding no statistically significant difference (HR 0.78; 95% CI 0.42-1.44) [7]. Chronic pancreatitis was reported in 2 liraglutide patients versus 1 placebo patient. Pancreatic cancer occurred in 13 liraglutide versus 5 placebo patients, a numerically higher but not statistically significant difference that may reflect ascertainment bias. Lipase and amylase elevations were more common with liraglutide but were not predictive of clinical pancreatitis. The FDA label carries a warning based on postmarketing reports, and liraglutide is contraindicated in patients with a history of pancreatitis. In the SCALE program (3.0 mg dose), pancreatitis was reported in 0.3% of liraglutide-treated patients vs 0.1% placebo [9].

Thyroid C-cell tumors (medullary thyroid carcinoma). In rodent carcinogenicity studies, liraglutide caused dose-dependent and treatment-duration-dependent thyroid C-cell hyperplasia and medullary thyroid carcinoma (MTC) at clinically relevant exposures. In rats, the incidence of C-cell adenomas and carcinomas was increased at all doses tested (0.1, 0.25, and 1.0 mg/kg/day), including doses producing exposures below the human therapeutic exposure. In mice, C-cell hyperplasia was observed but MTC was not. This carries a boxed warning on the US label -- the most prominent safety warning available. Liraglutide is contraindicated in patients with personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). The human relevance of the rodent MTC finding remains uncertain and is a matter of ongoing debate: human thyroid C-cells have substantially lower GLP-1 receptor expression than rodent C-cells, and the GLP-1 receptor-mediated calcitonin release that drives rodent C-cell proliferation has not been consistently demonstrated in humans. In LEADER (median 3.8-year follow-up), no imbalance in MTC or thyroid cancer was observed. Long-term epidemiological surveillance, including the Novo Nordisk-sponsored MTC registry and FDA FAERS database analyses, has not identified an increased risk of MTC in humans treated with liraglutide, though continued vigilance is warranted given the long latency of thyroid malignancies.

Gallbladder events. Gallbladder-related adverse events are a recognized risk with liraglutide, particularly at higher doses. In LEADER (1.8 mg), cholelithiasis occurred in 1.5% liraglutide vs 1.1% placebo, and cholecystitis in 0.8% vs 0.5%, representing modest absolute increases [7]. In the SCALE program (3.0 mg), gallbladder-related events were more frequent: cholelithiasis and cholecystitis were reported in approximately 2.5% of liraglutide-treated patients versus 1.0% placebo, with cholecystectomy rates of 1.4% vs 0.8% [9]. The increased gallbladder risk is likely related to both the degree and rate of weight loss (rapid weight loss promotes gallstone formation through bile supersaturation) and a possible direct GLP-1 receptor-mediated effect on gallbladder motility. The risk is proportional to the magnitude of weight loss achieved.

Heart rate increase. Liraglutide produces a modest increase in resting heart rate of 2-4 bpm on average, a class effect of GLP-1 RAs. In LEADER, mean heart rate increase was 3 bpm. The clinical significance is uncertain, but the overall cardiovascular outcomes in LEADER were clearly favorable.

Injection site reactions. Generally mild and infrequent, occurring in approximately 2% of patients.

Immunogenicity. Antibody formation is low-frequency and low-titer. Buse et al. (2011) reported that fewer than 10% of liraglutide-treated patients developed anti-liraglutide antibodies, which did not appear to affect efficacy or safety [22].

Renal safety. Liraglutide does not require dose adjustment for renal impairment, though caution is advised in severe renal impairment due to limited experience. Gastrointestinal adverse events (particularly vomiting and diarrhea) may lead to dehydration, which has been associated with acute kidney injury reports, particularly in patients with pre-existing renal disease.

Heart failure (FIGHT trial -- important safety signal). The FIGHT trial (n=300) specifically evaluated liraglutide in patients with advanced heart failure and reduced ejection fraction (HFrEF, median LVEF 25%) [17]. Liraglutide did NOT improve clinical stability and showed a trend toward harm: rehospitalization for heart failure was numerically higher with liraglutide (41% vs 34%; HR 1.30; 95% CI 0.89-1.88; p=0.17), and there was no benefit in the primary global rank endpoint (p=0.31). This constitutes a clinically important negative safety signal. Liraglutide (and by extension, GLP-1 RAs as a class) should not be used specifically to treat heart failure, and caution is advised when prescribing to patients with NYHA class III-IV heart failure or LVEF less than 30%. Notably, the LEADER trial excluded patients with NYHA class IV, and the overall cardiovascular benefit observed in LEADER was driven by atherosclerotic endpoints rather than heart failure outcomes [7][17].

Drug interactions. Because liraglutide is metabolized by endogenous peptidases (DPP-4, NEP) rather than CYP enzymes, traditional pharmacokinetic drug-drug interactions are minimal. The primary interaction mechanism is delayed gastric emptying, which may affect the absorption rate of concomitant oral medications. In clinical practice, patients on warfarin should be monitored with increased INR testing during liraglutide initiation and dose changes. Patients on oral hypoglycemics (particularly sulfonylureas) or insulin should be counseled about increased hypoglycemia risk when adding liraglutide, and dose reduction of the sulfonylurea or insulin may be necessary. Liraglutide is not known to interact with statins, ACE inhibitors, ARBs, or oral contraceptives to a clinically meaningful degree.

10. Regulatory Status

United States (FDA).

• January 25, 2010: Victoza (liraglutide 1.2 mg and 1.8 mg) approved for glycemic control in adults with type 2 diabetes as adjunct to diet and exercise.
• August 25, 2017: Victoza label updated to include cardiovascular indication -- reduction of risk of major adverse cardiovascular events (cardiovascular death, non-fatal MI, non-fatal stroke) in adults with type 2 diabetes and established cardiovascular disease, based on the LEADER trial.
• June 2019: Victoza approved for pediatric patients aged 10 years and older with type 2 diabetes.
• December 23, 2014: Saxenda (liraglutide 3.0 mg) approved for chronic weight management in adults with BMI >=30 kg/m2 or BMI >=27 kg/m2 with at least one weight-related comorbidity, as adjunct to reduced-calorie diet and increased physical activity.
• December 4, 2020: Saxenda indication expanded to include adolescents aged 12-17 years with body weight above 60 kg and obesity (BMI corresponding to >=30 kg/m2 for adults), based on the SCALE Teens trial.

European Union (EMA). Victoza was approved by the EMA on June 30, 2009, for treatment of type 2 diabetes in combination with oral antidiabetic agents or basal insulin. Saxenda was approved on March 23, 2015, for weight management. The EMA's Committee for Medicinal Products for Human Use (CHMP) has periodically reviewed the benefit-risk profile including pancreatitis and thyroid safety signals.

Japan. Victoza was approved in Japan in January 2010 (as 0.9 mg dose, later adjusted).

Generic liraglutide availability. In December 2024, three generic versions of liraglutide (Victoza reference) for type 2 diabetes became commercially available in the United States, with additional generics launched by Meitheal Pharmaceuticals in April 2025. In August 2025, Teva Pharmaceuticals received FDA approval for the first generic version of Saxenda (liraglutide injection) for chronic weight management -- making it the first-ever generic GLP-1 receptor agonist indicated for weight loss in adults and adolescents aged 12-17 years. Biocon received FDA approval for its generic liraglutide injection for weight management in February 2026. The availability of generic liraglutide is expected to significantly improve access and affordability, particularly as newer GLP-1 RAs (semaglutide, tirzepatide) remain under patent protection and command substantially higher prices.

Liraglutide is manufactured by Novo Nordisk A/S (Bagsvaerd, Denmark) using recombinant DNA technology in Saccharomyces cerevisiae yeast, followed by chemical acylation of the palmitic acid-glutamic acid side chain.

11. Related Peptides

See also: Semaglutide (Ozempic / Wegovy), Tirzepatide (Mounjaro / Zepbound)

12. References

1. [1] Marre M, Shaw J, Brandle M, et al. (2009). Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med. DOI PubMed
2. [2] Nauck M, Frid A, Hermansen K, et al. (2009). Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes (LEAD-2). Diabetes Care. DOI PubMed
3. [3] Garber A, Henry R, Ratner R, et al. (2009). Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono). Lancet. DOI PubMed
4. [4] Zinman B, Gerich J, Buse JB, et al. (2009). Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione (LEAD-4 Met+TZD). Diabetes Care. DOI PubMed
5. [5] Russell-Jones D, Vaag A, Schmitz O, et al. (2009). Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU). Diabetologia. DOI PubMed
6. [6] Buse JB, Rosenstock J, Sesti G, et al. (2009). Liraglutide once a day versus exenatide twice a day for type 2 diabetes (LEAD-6). Lancet. DOI PubMed
7. [7] Marso SP, Daniels GH, Tanaka K, et al. (2016). Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER). N Engl J Med. DOI PubMed
8. [8] Mann JFE, Orsted DD, Brown-Frandsen K, et al. (2017). Liraglutide and Renal Outcomes in Type 2 Diabetes. N Engl J Med. DOI PubMed
9. [9] Pi-Sunyer X, Astrup A, Fujioka K, et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE Obesity and Prediabetes). N Engl J Med. DOI PubMed
10. [10] le Roux CW, Astrup A, Fujioka K, et al. (2017). 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes. Lancet. DOI PubMed
11. [11] Davies MJ, Bergenstal R, Bode B, et al. (2015). Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes (SCALE Diabetes). JAMA. DOI PubMed
12. [12] Wadden TA, Hollander P, Klein S, et al. (2013). Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss (SCALE Maintenance). Int J Obes (Lond). DOI PubMed
13. [13] Blackman A, Foster GD, Zammit G, et al. (2016). Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea (SCALE Sleep Apnea). Int J Obes (Lond). DOI PubMed
14. [14] Kelly AS, Auerbach P, Barrientos-Perez M, et al. (2020). A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity (SCALE Teens). N Engl J Med. DOI PubMed
15. [15] Fox CK, Barrientos-Perez M, Gies I, et al. (2025). Liraglutide for Children 6 to &lt;12 Years of Age with Obesity. N Engl J Med. DOI PubMed
16. [16] Armstrong MJ, Gaunt P, Aithal GP, et al. (2016). Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN). Lancet. DOI PubMed
17. [17] Margulies KB, Hernandez AF, Redfield MM, et al. (2016). Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction (FIGHT). JAMA. DOI PubMed
18. [18] Dungan KM, Povedano ST, Forst T, et al. (2014). Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6). Lancet. DOI PubMed
19. [19] Pratley R, Amod A, Hoff ST, et al. (2019). Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4). Lancet. DOI PubMed
20. [20] Edison P, Femminella GD, Ritchie C, et al. (2026). Liraglutide in mild to moderate Alzheimer's disease (ELAD phase 2b). Nat Med. DOI PubMed
21. [21] Elkind-Hirsch KE, Chappell N, Shaler D, et al. (2022). Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome. Fertil Steril. DOI PubMed
22. [22] Buse JB, Garber A, Rosenstock J, et al. (2011). Liraglutide treatment is associated with a low frequency and magnitude of antibody formation. J Clin Endocrinol Metab. DOI PubMed
23. [23] Norgaard CH, Friedrich S, Hansen CT, et al. (2022). Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia. Alzheimers Dement (N Y). DOI PubMed
24. [24] Verma S, Poulter NR, Bain SC, et al. (2018). Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes and Polyvascular Disease (LEADER). Circulation. DOI PubMed
25. [25] Buse JB, Bain SC, Mann JFE, et al. (2020). Cardiovascular Risk Reduction With Liraglutide - Mediation Analysis (LEADER). Diabetes Care. DOI PubMed
26. [26] Kristensen SL, Rorth R, Jhund PS, et al. (2019). Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes - meta-analysis. Lancet Diabetes Endocrinol. DOI PubMed
27. [27] Khoo J, Hsiang JC, Taneja R, et al. (2019). Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non-alcoholic fatty liver disease. Liver Int. DOI PubMed
28. [28] Meza N, Carrasco-Labra A, Bravo-Soto G, et al. (2025). Liraglutide for adults living with obesity (Cochrane Review). Cochrane Database Syst Rev. PubMed
29. [29] Danne T, Biester T, Kapitzke K, et al. (2017). Liraglutide in an Adolescent Population with Obesity - A Randomized, Double-Blind, Placebo-Controlled 5-Week Trial to Assess Safety, Tolerability, and Pharmacokinetics. J Pediatr. DOI PubMed
30. [30] Garber A, Henry RR, Ratner R, et al. (2011). Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy (LEAD-3 extension). Diabetes Obes Metab. DOI PubMed
31. [31] Rubino DM, Greenway FL, Khalid U, et al. (2022). Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes (STEP 8). JAMA. DOI PubMed
32. [32] Capehorn MS, Catarig AM, Furberg JK, et al. (2020). Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1-3 oral antidiabetic medications in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab. DOI PubMed
33. [33] Teva Pharmaceutical Industries Ltd. (2025). Teva Announces FDA Approval and Launch of Generic Saxenda (liraglutide injection) -- First Generic GLP-1 Indicated for Weight Loss. Press Release. PubMed